Antibody characterization is often described as a collection of analytical tests. For non-IgG antibodies, however, it is more useful to think of characterization as a decision-making framework. IgA, IgM, IgE, IgY, andRead More…
Non-IgG antibodies are gaining increasing attention in immunology, oncology research, mucosal immunity, allergy studies, infectious disease research, and diagnostic assay development. Unlike conventional IgG molecules, complex isotypes such as IgA, IgM, andRead More…
Introduction: Moving Beyond the IgG-Centered Bioprocessing Model For decades, antibody production has been largely shaped by the success of IgG monoclonal antibodies. Most expression platforms, purification workflows, analytical assays, and scale-up strategiesRead More…
Non-IgG antibodies are gaining increasing attention in therapeutic discovery and biotechnological research because they offer structural flexibility, compact molecular size, modular design potential, and unique biological advantages that conventional IgG antibodies mayRead More…
For decades, the therapeutic antibody landscape has been heavily dominated by the Immunoglobulin G (IgG) isotype. Its long serum half-life, well-understood pharmacokinetics, and manageable structural properties have made it the gold standardRead More…
The landscape of therapeutic antibodies is rapidly evolving. For decades, the biopharmaceutical industry has heavily relied on the standard Immunoglobulin G (IgG) framework to develop life-saving treatments for oncology, autoimmune diseases, andRead More…
For decades, the biopharmaceutical landscape has been dominated by Immunoglobulin G (IgG). Its favorable half-life, well-understood structure, and established manufacturing processes have made it the gold standard for monoclonal antibody (mAb) therapeutics. However,Read More…
Non-IgG antibodies—especially IgA, IgM, and IgE—are re-entering biologics pipelines for reasons IgG cannot always match: mucosal targeting, high avidity through multivalency, and specialized effector biology. But the same structural features that makeRead More…
IgG has been the “default chassis” for therapeutic antibodies for decades—and for good reason: mature discovery workflows, predictable developability, well-characterized Fc effector biology, and scalable manufacturing. But the industry’s IgG-centric comfort zoneRead More…
Antimicrobial resistance (AMR) is steadily eroding the impact of conventional antibiotics. Every year, hundreds of thousands of deaths are already attributed to drug-resistant infections, and projections indicate that, without new strategies, thisRead More…